Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Gurupup who wrote (1408)	3/17/1998 3:49:00 PM
From: Gurupup	Read Replies (1) \| Respond to of 5736

Here is one more. I see an interesting polarization here about this company which appears separate from the motives of self-gain (shorting). I must agree that the term "chromogenic disease" is disturbing to those of us in the field of medicine. Here are my thoughts for what it's worth: 1. In the shareholder letter, the company refers to "non-invasive MONITORING (not diagnosis) of chromogenic diseases based on color science." They are not hyping their technology to imply that they are going to diagnose ANYTHING..only offer a less invasive monitoring technology. The shorters have twisted the term to obviously make it look like a major hype-job. Research Magazine, October 19, 1997, however, did make statements claiming "diagnosis of skin, tissue, or fluids such as anemia, hepatitis, tuberculosis, forms of malignancy" etc. etc. They also went on to speculate about a hand held color computer for matching wardrobe, paint speciments, carpet etc. This, to me, IS hype, but it did not come from the company. I agree that it is absurd to make such claims. This, unfortunately, has led some away from this unique opportunity. 2. I am an obstetrician who has delivered many jaundiced babies over the last 19 years. Our pediatrician for our kids has a 39 year old daughter with profound cerebral palsy resulting from the deposits of bilirubin pigment in brain tissue (kernicterus). This was an unrecognized cause of brain damage years ago. I am painfully reminded of the frequent heel-sticks one of my children endured as a result of physiologic jaundice of the newborn. I personally think that there IS a huge market for non-invasive testing but it is beyond me to place a number. One third of all babies have physiologic jaundice and must be monitored. Greater than half of all asian infants suffer physiologic jaundice. I think the world market may be very significant. My impressions so far are that the management doesn't hype, that they have top-notch professionals leading their research, and that they have a breakthrough application for hyperbilirubinemia. I do not see a medical application much beyond that, however. I am staking a bet on the accuracy of their market analysis, and if they later come up a pocket color coordinator that will help me match my socks in the morning - GREAT. (How many guys do you know that are color-blind?) Thats not what I am investing for, however. Don't be misled by what is fed to us by investors (pro and con). Look at what the company is saying and doing.